The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

被引：155

作者：

Jordheim, Lars Petter ^{[1
,2
]}

Seve, Pascal ^{[2
,3
]}

Tredan, Olivier ^{[5
]}

Dumontet, Charles ^{[2
,4
]}

机构：

[1] Univ Lyon 1, Fac Med Rockefeller, Lab Cytol Analyt, INSERM,U590, F-69008 Lyon, France

[2] Lyon Univ, Lyon, France

[3] Hosp Civils Lyon, Dept Internal Med, Lyon, France

[4] Hosp Civils Lyon, Hematol Lab, Lyon, France

[5] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France

来源：

LANCET ONCOLOGY | 2011年 / 12卷 / 07期

关键词：

CELL LUNG-CANCER; MESSENGER-RNA EXPRESSION; HUMAN PANCREATIC-CANCER; GEMCITABINE-BASED CHEMOTHERAPY; CHROMOSOME SEGMENT 11P15.5; ANTITUMOR-ACTIVITY; MOLECULAR MARKERS; SINGLE NUCLEOTIDE; ERCC1; EXPRESSION; RANDOMIZED-TRIAL;

D O I：

10.1016/S1470-2045(10)70244-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of cell proliferation, cell migration, tumour and metastasis development, and the synthesis of deoxyribonucleotides for DNA synthesis. It is also a cellular target for the chemotherapeutic agent, gemcitabine. RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and biliary tract cancer, to establish its prognostic or predictive value when patients were treated with gemcitabine, and mRNA expression and genetic variants as determined by genotyping have in some cases been associated with clinical outcome of patients with cancer. Here, we review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker.

引用

页码：693 / 702

页数：10

共 78 条

[1] Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma [J].

Akita, H. ;

Zheng, Z. ;

Takeda, Y. ;

Kim, C. ;

Kittaka, N. ;

Kobayashi, S. ;

Marubashi, S. ;

Takemasa, I. ;

Nagano, H. ;

Dono, K. ;

Nakamori, S. ;

Monden, M. ;

Mori, M. ;

Doki, Y. ;

Bepler, G. .

ONCOGENE, 2009, 28 (32) :2903-2909

[2] Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer [J].

Ashida, Reiko ;

Nakata, Bunzo ;

Shigekawa, Minoru ;

Mizuno, Nobumasa ;

Sawaki, Akira ;

Hirakawa, Kosei ;

Arakawa, Tetsuo ;

Yamao, Kenji .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28

[3] XPG mRNA Expression Levels Modulate Prognosis in Resected Non-Small-Cell Lung Cancer in Conjunction with BRCA1 and ERCC1 Expression [J].

Bartolucci, Roberta ;

Wei, Jia ;

Sanchez, Jose Javier ;

Perez-Roca, Laia ;

Chaib, Imane ;

Puma, Francesco ;

Farabi, Raffaele ;

Mendez, Pedro ;

Roila, Fausto ;

Okamoto, Tatsuro ;

Taron, Miquel ;

Rosell, Rafael .

CLINICAL LUNG CANCER, 2009, 10 (01) :47-52

[4] Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine [J].

Bender, David M. ;

Bao, Jingqi ;

Dantzig, Anne H. ;

Diseroad, William D. ;

Law, Kevin L. ;

Magnus, Nicholas A. ;

Peterson, Jeffrey A. ;

Perkins, Everett J. ;

Pu, Yangwei J. ;

Reutzel-Edens, Susan M. ;

Remick, David M. ;

Starling, James J. ;

Stephenson, Gregory A. ;

Vaid, Radhe K. ;

Zhang, Deyi ;

McCarthy, James R. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :6958-6961

[5] Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance [J].

Bepler, G ;

Zheng, Z ;

Gautam, A ;

Sharma, S ;

Cantor, A ;

Sharma, A ;

Cress, WD ;

Kim, YC ;

Rosell, R ;

McBride, C ;

Robinson, L ;

Sommers, E ;

Haura, E .

LUNG CANCER, 2005, 47 (02) :183-192

[6] RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer [J].

Bepler, G ;

Sharma, S ;

Cantor, A ;

Gautam, A ;

Haura, E ;

Simon, G ;

Sharma, A ;

Sommers, E ;

Robinson, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1878-1885

[7] Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer [J].

Bepler, G ;

Gautam, A ;

McIntyre, LM ;

Beck, AF ;

Chervinsky, DS ;

Kim, YC ;

Pitterle, DM ;

Hyland, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1353-1360

[8] Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer [J].

Bepler, Gerold ;

Sommers, K. Eric ;

Cantor, Alan ;

Li, Xueli ;

Sharma, Anupama ;

Williams, Charles ;

Chiappori, Alberto ;

Haura, Eric ;

Antonia, Scott ;

Tanvetyanon, Tawee ;

Simon, George ;

Obasaju, Coleman ;

Robinson, Lary A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1112-1118

[9] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[10] In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant [J].

Bergman, AM ;

Eijk, PP ;

van Haperen, VWTR ;

Smid, K ;

Veerman, G ;

Hubeek, I ;

van den Ijssel, P ;

Ylstra, B ;

Peters, GJ .

CANCER RESEARCH, 2005, 65 (20) :9510-9516

← 1 2 3 4 5 6 7 8 →